Vanda Pharmaceuticals Launches NEREUS for Motion Sickness After 40 Years

Vanda Pharmaceuticals said NEREUS™ is now commercially available across the United States for adults with motion sickness. The launch comes after the U.S. Food and Drug Administration approved tradipitant on December 30, 2025. For patients, the shift is immediate: a prescription drug that was cleared in late 2025 can now be filled nationwide or ordered directly.

Mihael H. Polymeropoulos on the launch

Mihael H. Polymeropoulos, president, chief executive and chairman of Vanda, said, "Today marks an important milestone for the tens of millions of Americans who experience motion sickness symptoms during common travel". He added that "NEREUS™ is a selective, high-affinity antagonist of human substance P/neurokinin-1 (NK-1) receptors that can block the vomiting center of the brain."

Vanda says the drug is available by prescription through nereus.us and retail pharmacies nationwide. Patients with a valid prescription can access it for $85 per dose through the company’s direct channel, compared with a standard list price of $255 per dose.

40 years without a new option

Vanda said NEREUS™ is the first new prescription medicine approved for motion sickness in more than 40 years. The company also said the drug is an oral neurokinin-1 receptor antagonist and that the approval followed two pivotal Phase 3 clinical trials, Motion Syros and Motion Serifos.

Those studies were conducted under real-world conditions on the open sea, and Vanda said both demonstrated that NEREUS™ significantly prevented vomiting compared with placebo. The launch now gives adults a new prescription option in a condition that affects an estimated 65 to 78 million Americans, including roughly 25 to 30 percent of adults.

Retail pharmacies and nereus.us

Vanda said, "We are excited to make this innovative therapy available through both traditional pharmacy channels and our new direct-to-consumer platform at nereus.us, giving travelers, families, and anyone affected by motion sickness convenient access to a long-awaited solution." That leaves the commercial question focused on uptake: whether patients use the pharmacy route or the lower cash-pay price online.